{"filing":{"accession_number":"0001062993-26-003132","cik":"0001728328","ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326003132/form8k.htm"},"events":[{"id":5582,"run_id":4898,"accession_number":"0001062993-26-003132","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"InMed received a Nasdaq notice on March 27, 2026 that its closing bid price fell below the $1.00 minimum requirement under Nasdaq Listing Rule 5550(a)(2), creating delisting risk. Although the Company subsequently regained compliance by June 3, 2026, the disclosure centers on the failure to satisfy a continued listing rule and the remediation thereof—the core substance of delisting_risk. This is material to investors as it directly affects the registrant's exchange listing status.","company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","filing_date":"2026-06-10","submitted_at":null,"items":[{"id":5702,"accession_number":"0001062993-26-003132","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"InMed received a Nasdaq notice on March 27, 2026 that its closing bid price fell below the $1.00 minimum requirement under Nasdaq Listing Rule 5550(a)(2), creating delisting risk. Although the Company subsequently regained compliance by June 3, 2026, the disclosure centers on the failure to satisfy a continued listing rule and the remediation thereof—the core substance of delisting_risk. This is material to investors as it directly affects the registrant's exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:06:11.641618+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5702,"accession_number":"0001062993-26-003132","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"InMed received a Nasdaq notice on March 27, 2026 that its closing bid price fell below the $1.00 minimum requirement under Nasdaq Listing Rule 5550(a)(2), creating delisting risk. Although the Company subsequently regained compliance by June 3, 2026, the disclosure centers on the failure to satisfy a continued listing rule and the remediation thereof—the core substance of delisting_risk. This is material to investors as it directly affects the registrant's exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:06:11.641618+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","filing_date":"2026-06-10"}]}